Isolated thrombocytopenia after hematopoietic stem cell transplantation (HSCT) is defined as consistently low platelet counts after transplantation, with recovery of all other peripheral blood cell lines.
1 It represents a challenging clinical problem because it often leads to an increased risk of life-threatening hemorrhage, frequent requirement of platelet transfusions, and extended hospital stays. 2 Previous studies have demonstrated that decitabine, a hypomethylating agent, can increase platelet counts by enhancing platelet release and megakaryocyte maturation in mice. 3 Herein, we report a pilot study showing efficacy of decitabine in patients with isolated thrombocytopenia post-HSCT.
Methods | An open-label study was designed to evaluate decitabine treatment for isolated thrombocytopenia in allogeneic HSCT patients with hematological malignant neoplasms. The inclusion criteria were (1) primary or secondary platelet count of 30 × 10 3 /μL or less persistently at day 60 post-HSCT or later; (2) recovered neutrophil and hemoglobin; (3) full donor chimerism; and (4) no response to conventional therapies (eg, thrombopoietin, immunoglobulin, rituximab, plasma exchange alone or in combination) for a duration of at least 4 weeks. Patients with relapse of their malignant disease, active infections, uncontrolled graft-vshost disease (GVHD), severe organ damage, or transplantrelated thrombosis were excluded. Enrolled patients were distributed into either the control group to receive the conventional therapies or the treatment group to receive additional decitabine (15 mg/m 2 daily intravenously for 3 consecutive days) in random. All participants provided written informed consent in accordance with the Declaration of Helsinki, and the study protocol was approved by the ethics committee of The First Affiliated Hospital of Soochow University, Suzhou, China. Peripheral blood cell counts, virology, antiplatelet antibodies, and T-cell subsets were analyzed routinely. Bone marrow puncture was performed before treatment (week 0) and then repeated at week 4. Platelet responses were evaluated according to an international working group guideline within a 8-week study period. 4 Results | From July 2013 through February 2014 at our hospital, 251 patients received allogeneic HSCT, and 72 of them developed isolated thrombocytopenia afterward. During this period, 22 patients (Table) were enrolled in this study based on the criteria described herein. The response rate was 100% in the decitabine group vs 27.3% in the control group (P = .001). In the treatment group, platelet counts increased significantly 4 weeks after decitabine injections ( Figure) , with a median time of 22 days to achieve platelet transfusionindependence, and maintained until the sixth month, except for the patient with minor response.
In bone marrow morphological analysis, patients in both groups revealed low levels of megakaryocytes at week 0. However, the significantly increasing megakaryocyte level, especially the "platelet shedding" megakaryocyte, was observed only in decitabine group at week 4 ( Figure) . Transplantationrelated complications (eg, chronic GVHD), antiplatelet antibodies, and T-cell subsets did not noticeably change after decitabine treatment. No clinically significant myelosuppression, febrile neutropenia, or nonhematologic toxic effects were observed during the study period.
Discussion | Our study shows a very encouraging result of decitabine in increasing peripheral platelets in HSCT recipients, with remarkably increased megakaryocyte counts. There was no evident change in antiplatelet antibodies and T-cell subtypes after decitabine administration, implying that decitabine functions independent of immune regulation. In mice, decitabine was found to induce megakaryocyte differentiation and promote platelets release.
3 This mechanism may have contributed to our results. Myelosuppression is the main concern of decitabine. Low-dose decitabine could optimize clinical responses with less toxic effects. 5 Based on previous studies, we used 15 mg/m 2 for 3 days, which was well tolerated by the participants.
Although the sample size of this study is small, with a relatively short follow-up, the clinically significant platelet recovery following decitabine treatment suggest potentially important clinical benefits and warrant the necessity for a large-scale clinical trial of this promising therapy. 
Suggestibility of Oncologists' Clinical Estimates
Quantitative estimates, including prognosis and likelihood of clinical outcomes, are an integral part of oncologic counseling and treatment. In general, estimates should be grounded in the best available data, adjusted as necessary for individual patients' circumstances. However, it is well established that judgments are often biased by unrelated or uninformed numerical anchors (eg, guesses). 1,2 There is good reason to suspect that physicians' clinical assessments may be influenced by cognitive shortcuts, or heuristics. We therefore sought Methods | Members of the New England and Mid-Atlantic Associations of Gynecologic Oncologists received emails containing an electronic link to 1 of 2 survey forms. Each survey included 2 clinical scenarios. Respondents were not compensated for their participation.
Scenario 1 described a 77-year-old woman with platinumresistant serous ovarian carcinoma who expressed a desire to live either an additional 2 months or 30 months (randomized). Respondents indicated whether they believed that the patient would live as long as desired and provided their estimate of the patient's life expectancy. Scenario 2 described a patient who had recently had cytoreductive surgery for serous ovarian carcinoma with symptoms clinically ambiguous for pulmonary embolism. Respondents were told that a medical student believed that the patient had either a 1% or 95% likelihood of pulmonary embolism (randomized). Respondents indicated whether they believed that the medical student's estimate was too high or too low, provided their own estimate of the likelihood of pulmonary embolism, and indicated whether they would order diagnostic imaging or initiate therapeutic anticoagulation (vs expectant management alone) for the patient described. Means were calculated for each group and tested for significant difference using t tests for prognostic estimates and 2-proportion z tests for ordering decisions. The partners institutional review board exempted this study from final review.
Results | Responses were obtained from 58 staff gynecologic oncologists, for a response rate of 34%. In scenario 1 (Figure, A) , the mean (SD) estimated life expectancy of the patient who desired to live at least 2 additional months was 11.5 (4.9) months (median, 12.0 months) vs 15.4 (7.8) months (median, 18.0 months) for the patients who desired to live at least 30 additional months (P = .02).
In scenario 2 (Figure, B) , when the medical student believed there was a 1% chance of pulmonary embolism (PE), the oncologists' mean estimate was 18% (21%) (median, 10%). This increased to 33% (25%) (median, 25%) when the medical student believed there was a 95% chance of PE (P = .02). There was no significant difference in ordering diagnostic imaging or therapeutic anticoagulation between the 2 groups (65% vs 48%; P = .21). Information on nonresponders was not available. However, respondents were evenly distributed over time since completing training; this variable did not consistently affect estimates.
Discussion | Oncologists' clinical judgments, including estimates of life expectancy, seem to be susceptible to influence by extraneous information consistent with anchoring bias, a heuristic very well characterized in cognitive psychology. Quantitative estimates are likely to be disproportionately influenced by initially presented values, irrespective of relevance or reliability. This study was limited by low response rate and small sample size. Nevertheless, the results suggest that extensive training and availability of data may not protect clinicians from nonrational clinical decision-making. Rather, whenever there is clinical uncertainty, there is potential for cognitive bias. 4 Furthermore, awareness alone is not sufficient to avoid bias. Existing data suggest that the anchoring effect is robust and refractory to many possible corrective strategies. However, one approach that has shown some promise is to "consider the opposite. 
